 Matthew McLaughlin
Concepts (122)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cerebral Palsy | 7 | 2023 | 18 | 4.940 |
Why?
| | Baclofen | 5 | 2023 | 9 | 2.330 |
Why?
| | Brain Injuries | 3 | 2023 | 8 | 1.880 |
Why?
| | Muscle Relaxants, Central | 3 | 2023 | 7 | 1.760 |
Why?
| | Botulinum Toxins, Type A | 2 | 2023 | 5 | 1.590 |
Why?
| | Child | 20 | 2023 | 3348 | 1.570 |
Why?
| | Humans | 26 | 2023 | 6929 | 1.420 |
Why?
| | Pharmacogenetics | 3 | 2019 | 171 | 1.230 |
Why?
| | Retrospective Studies | 11 | 2023 | 1337 | 1.130 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2020 | 96 | 0.970 |
Why?
| | Neurogenic Bowel | 1 | 2023 | 3 | 0.900 |
Why?
| | Myelitis | 1 | 2023 | 5 | 0.900 |
Why?
| | Central Nervous System Viral Diseases | 1 | 2023 | 6 | 0.900 |
Why?
| | Neuromuscular Diseases | 1 | 2023 | 7 | 0.900 |
Why?
| | Practice Patterns, Physicians' | 2 | 2023 | 85 | 0.890 |
Why?
| | Torticollis | 1 | 2023 | 1 | 0.880 |
Why?
| | Pandemics | 2 | 2020 | 81 | 0.840 |
Why?
| | Alphapapillomavirus | 1 | 2022 | 1 | 0.820 |
Why?
| | Papillomavirus Infections | 1 | 2022 | 6 | 0.810 |
Why?
| | Papillomavirus Vaccines | 1 | 2022 | 6 | 0.810 |
Why?
| | Medical Informatics | 1 | 2021 | 7 | 0.760 |
Why?
| | Spinal Dysraphism | 1 | 2021 | 8 | 0.760 |
Why?
| | Pediatrics | 2 | 2020 | 183 | 0.720 |
Why?
| | Neuromuscular Agents | 1 | 2020 | 1 | 0.720 |
Why?
| | Rehabilitation | 1 | 2020 | 1 | 0.720 |
Why?
| | Research Support as Topic | 1 | 2020 | 5 | 0.720 |
Why?
| | Drug Discovery | 1 | 2020 | 4 | 0.710 |
Why?
| | Electrodiagnosis | 1 | 2019 | 4 | 0.700 |
Why?
| | Accreditation | 1 | 2019 | 4 | 0.700 |
Why?
| | United States | 5 | 2023 | 670 | 0.680 |
Why?
| | Referral and Consultation | 1 | 2019 | 32 | 0.680 |
Why?
| | Drug Delivery Systems | 1 | 2019 | 6 | 0.670 |
Why?
| | Precision Medicine | 1 | 2019 | 43 | 0.640 |
Why?
| | Infant | 6 | 2023 | 1449 | 0.610 |
Why?
| | Adolescent | 7 | 2023 | 2183 | 0.550 |
Why?
| | Arteriovenous Malformations | 1 | 2015 | 1 | 0.510 |
Why?
| | Thoracic Vertebrae | 1 | 2015 | 5 | 0.510 |
Why?
| | Spinal Cord | 1 | 2015 | 6 | 0.510 |
Why?
| | Cervical Vertebrae | 1 | 2015 | 7 | 0.510 |
Why?
| | Physical Therapy Modalities | 1 | 2014 | 4 | 0.480 |
Why?
| | Young Adult | 6 | 2023 | 641 | 0.480 |
Why?
| | Probability | 1 | 2014 | 15 | 0.480 |
Why?
| | Models, Statistical | 1 | 2014 | 29 | 0.470 |
Why?
| | Female | 8 | 2023 | 3534 | 0.390 |
Why?
| | Prognosis | 2 | 2023 | 216 | 0.360 |
Why?
| | Administration, Oral | 2 | 2020 | 58 | 0.330 |
Why?
| | Male | 7 | 2023 | 3367 | 0.330 |
Why?
| | Child, Preschool | 4 | 2023 | 1562 | 0.310 |
Why?
| | Inpatients | 3 | 2023 | 43 | 0.290 |
Why?
| | Genetic Variation | 2 | 2019 | 166 | 0.290 |
Why?
| | Methylphenidate | 1 | 2023 | 2 | 0.230 |
Why?
| | Central Nervous System Stimulants | 1 | 2023 | 11 | 0.230 |
Why?
| | Down Syndrome | 1 | 2023 | 39 | 0.220 |
Why?
| | Infusion Pumps, Implantable | 1 | 2023 | 2 | 0.220 |
Why?
| | Muscle Spasticity | 1 | 2023 | 3 | 0.220 |
Why?
| | Injections | 1 | 2023 | 5 | 0.220 |
Why?
| | Urinary Bladder, Neurogenic | 1 | 2022 | 3 | 0.220 |
Why?
| | Spinal Cord Injuries | 1 | 2022 | 4 | 0.210 |
Why?
| | Immunization | 1 | 2022 | 25 | 0.200 |
Why?
| | Amantadine | 1 | 2021 | 1 | 0.200 |
Why?
| | Radiotherapy, Image-Guided | 1 | 2021 | 2 | 0.200 |
Why?
| | Vaccination | 1 | 2022 | 70 | 0.200 |
Why?
| | Motor Disorders | 1 | 2021 | 3 | 0.190 |
Why?
| | Cognition Disorders | 1 | 2021 | 12 | 0.190 |
Why?
| | Appointments and Schedules | 1 | 2021 | 13 | 0.190 |
Why?
| | Treatment Outcome | 1 | 2023 | 649 | 0.190 |
Why?
| | Ambulatory Care Facilities | 1 | 2021 | 37 | 0.190 |
Why?
| | Tomography, X-Ray Computed | 1 | 2021 | 130 | 0.180 |
Why?
| | Disability Evaluation | 1 | 2020 | 14 | 0.180 |
Why?
| | Atmospheric Pressure | 1 | 2020 | 1 | 0.180 |
Why?
| | Personal Protective Equipment | 1 | 2020 | 1 | 0.180 |
Why?
| | Hydroxychloroquine | 1 | 2020 | 1 | 0.180 |
Why?
| | Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 1 | 0.180 |
Why?
| | Body Weight | 1 | 2020 | 52 | 0.180 |
Why?
| | Adenosine Monophosphate | 1 | 2020 | 2 | 0.180 |
Why?
| | Alanine | 1 | 2020 | 3 | 0.180 |
Why?
| | Public-Private Sector Partnerships | 1 | 2020 | 2 | 0.180 |
Why?
| | Metabolome | 1 | 2020 | 5 | 0.180 |
Why?
| | Off-Label Use | 1 | 2020 | 5 | 0.180 |
Why?
| | Injections, Intramuscular | 1 | 2020 | 5 | 0.180 |
Why?
| | Antimalarials | 1 | 2020 | 7 | 0.180 |
Why?
| | Vulnerable Populations | 1 | 2020 | 7 | 0.180 |
Why?
| | Drug Administration Schedule | 1 | 2020 | 36 | 0.180 |
Why?
| | Tandem Mass Spectrometry | 1 | 2020 | 20 | 0.180 |
Why?
| | Antiviral Agents | 1 | 2020 | 26 | 0.180 |
Why?
| | Muscles | 1 | 2019 | 3 | 0.180 |
Why?
| | Patient Selection | 1 | 2020 | 34 | 0.170 |
Why?
| | Case-Control Studies | 1 | 2020 | 216 | 0.170 |
Why?
| | Missouri | 1 | 2019 | 77 | 0.170 |
Why?
| | Molecular Targeted Therapy | 1 | 2019 | 10 | 0.170 |
Why?
| | Research Design | 1 | 2019 | 63 | 0.160 |
Why?
| | Cross-Sectional Studies | 1 | 2020 | 333 | 0.160 |
Why?
| | Age Factors | 1 | 2019 | 211 | 0.160 |
Why?
| | Sulfonylurea Receptors | 1 | 2017 | 3 | 0.150 |
Why?
| | Pharmacological Phenomena | 1 | 2017 | 1 | 0.150 |
Why?
| | Pharmacokinetics | 1 | 2017 | 14 | 0.150 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2017 | 348 | 0.130 |
Why?
| | Quadriplegia | 1 | 2015 | 1 | 0.130 |
Why?
| | Magnetic Resonance Imaging | 1 | 2015 | 122 | 0.120 |
Why?
| | Rehabilitation Centers | 2 | 2023 | 3 | 0.110 |
Why?
| | Recovery of Function | 2 | 2021 | 22 | 0.100 |
Why?
| | Length of Stay | 2 | 2023 | 243 | 0.100 |
Why?
| | Range of Motion, Articular | 1 | 2023 | 13 | 0.060 |
Why?
| | Mandelic Acids | 1 | 2022 | 1 | 0.050 |
Why?
| | Urodynamics | 1 | 2022 | 1 | 0.050 |
Why?
| | Fiducial Markers | 1 | 2021 | 2 | 0.050 |
Why?
| | Endosonography | 1 | 2021 | 2 | 0.050 |
Why?
| | Needles | 1 | 2021 | 3 | 0.050 |
Why?
| | Beverages | 1 | 2021 | 2 | 0.050 |
Why?
| | World Health Organization | 1 | 2021 | 8 | 0.050 |
Why?
| | Cognition | 1 | 2021 | 32 | 0.050 |
Why?
| | Cost of Illness | 1 | 2021 | 19 | 0.050 |
Why?
| | Diet | 1 | 2021 | 54 | 0.050 |
Why?
| | Predictive Value of Tests | 1 | 2021 | 102 | 0.050 |
Why?
| | Cohort Studies | 1 | 2021 | 281 | 0.050 |
Why?
| | Stereoisomerism | 1 | 2020 | 11 | 0.040 |
Why?
| | Chromatography, Liquid | 1 | 2020 | 10 | 0.040 |
Why?
| | Calibration | 1 | 2020 | 7 | 0.040 |
Why?
| | Drug Monitoring | 1 | 2020 | 12 | 0.040 |
Why?
| | Prospective Studies | 1 | 2021 | 547 | 0.040 |
Why?
| | Hospitalization | 1 | 2021 | 209 | 0.040 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2017 | 39 | 0.040 |
Why?
|
|
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|